Rafi Bamdad

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

Mantra Bio is harnessing exosomes to deliver safe, highly targeted medicines. We are the creator of REVEAL™, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas.

Chimeras mission is to reprogram life to end cancer, using therapies that restore dignity to patients. We do this with next generation, safer and more potent, CAR T therapeutics.

Our Story: Dr. Rafael Squitieri, Chief of Cardiothoracic Surgery at St. Vincent's Medical Center in Bridgeport, CT, was inspired to transform Critical Care. His inspiration was based on an unforgettable experience with a young patient who underwent successful open-heart surgery but suffered afterward due to complications from a sacral pressure injury. Determined to find a solution for this very common challenge that occurs despite clinicians' best manual efforts and use of the latest therapeutic equipment, Dr. Squitieri set out to devise a system that focuses on preventing blood flow impairment to address the true, underlying problem causing hospital-acquired pressure injuries. In 2011, Dr. Squitieri teamed up with Kim Orumchian, serial entrepreneur and technology expert, to found TurnCare with a vision of creating innovative solutions to protect the most complex critical care patients. Out of their combined vision, they created the Guardian System, which is uniquely designed to prevent sacral region blood flow impairment, providing greater flexibility for clinicians. To date, Dr. Squitieri has helped thousands of patients using this radically different approach; meanwhile improving patient management for bedside clinicians. Contact: TurnCare, Inc. 2225 E. Bayshore Road, Suite 200 Palo Alto, California (203) 505-4657 turncare.com info@turncare.com

Vave Health is a healthcare technology startup based in the Silicon Valley. And were hiring! We believe every patient deserves the best care, and every healthcare professional should have the best tools to provide it...wherever, whenever. With a focus on personal, portable and wireless ultrasound solutions, our aim is to impact the paradigm of healthcare on a global level by making superior imaging technology affordable and accessible to everyone.

Pyze is the leading Digital Transformation analytics platform to maximize process efficiency and application productivity through low-code process mining and usage analytics. Pyze auto-discovers complex end-to-end business process flows to surface process bottlenecks, activity hotspots, and user experience optimization opportunities. Pyze enables continuous improvement across multi-screen product journeys by providing a data-driven approach to maximize ROI and Business impact, regardless of the underlying technologies. Pyze has been recognized by leading technology research firms (Gartner and Forrester) and press as the leader in Cross-Platform Behavioral Analytics, Marketing and Process Intelligence Solutions.

Naked Biome is a microbiome-based skin therapeutics company. We are building the most advanced drug discovery genomics platform for the treatment of skin diseases and restoration of health. Our proprietary approach to skin therapy leverages the power of beneficial bacteria on the skin to eliminate harmful bacteria and restore skin to a healthier state. We have successfully completed a Phase IB for our first indication, acne, with a topical live biologic therapeutic, demonstrating positive safety and positive trends in all of our measures for efficacy (investigator global assessment of acne, lesion counts, and a shift to a healthy microbiome profile).

Convergent Genomics is a precision medicine company that combines advances in genomics and machine learning to detect cancer early and non-invasively. Convergent is a leader in applying these technologies for use in liquid biopsy from urine. Using genomic data, our products further integrate clinical scenarios and scientific literature to richly contextualize a patient’s specific risk and enable unique data-driven decision-making. Our Mission: Transforming cancer care through clear and actionable insights.

Lyten is an Advanced Materials company helping to decarbonize the planet by transforming greenhouse gases into Lyten 3D Graphene™, the most advanced carbon platform in the world, and using this material to develop highly innovative products that transform multiple industries. Batteries for Electric Vehicles (EV) Using our proprietary Lyten 3D Graphene™, we are developing an advanced Lithium-Sulfur battery that can be used by electric vehicles in the automotive, aviation, and aerospace industries. Composite Materials Using our proprietary Lyten 3D Graphene™, we are developing new polyethylene composite materials that will reduce the weight of plastic products while simultaneously maintaining stiffness, impact, and durability. Advanced Gas & Resonant Sensors Using our proprietary Lyten 3D Graphene™, we are developing multiple types of advanced resonant sensors, bio-sensors, and gas sensors that will have a tremendous impact in the health, safety, logistics, and manufacturing industries.

Xcell Biosciences (xcellbio) is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell’s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing. For more information, please visit http://www.xcellbio.com/.

Atheer’s Service Performance Platform is used by leading equipment manufacturers to deliver exceptional and profitable customer service across their field, dealer, partner and installer networks

Bouju is comprised of individuals who think differently and approach everyday problems in unique ways. What drives us everyday and holds us together is our passion for inventing new solutions to help some of the most amazing companies on earth flourish. We love it when companies create beautiful products that make people happy. We love it when a client invents cut resistant and fireproof material that saves lives. Or we love those jerseys that another client makes for our favorite sports teams. We wear them too. They are a part our culture. We are as passionate about these products as our clients and it personally hurts us when we see great companies lose sales to counterfeiters. We have, therefore, made it our mission to do everything in our power to help our clients continue making those beautiful products. That's why we have made our own beautiful products to protect you. As an executive reading this, if you share our beliefs and if you are really passionate about protecting the products your company makes, then we are ready to fight for you.

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

We are excited to announce that Marvell Semiconductor has acquired Aquantia! Follow Marvell: http://bit.ly/LN-Marvell Aquantia was founded with the vision of revolutionizing Ethernet and accelerating connectivity. As mobility and data consolidation in the cloud continues to gain momentum, we’re addressing the need for Multi-Gig Ethernet solutions that serve a variety of markets and products at both ends of the network, where data is stored and consumed, and where bottlenecks are created. Today, as the leader in Multi-Gig connectivity we provide solutions for Data Center, Enterprise Infrastructure, Access . Every year, more than a billion ports of Ethernet ship into a wide variety of platforms. These platforms have started to convert from outdated Gigabit Ethernet to Multi-Gigabit Ethernet as the insatiable demand for bandwidth and data continues to grow. Looking to the future, we will continue to address the Multi-Gig upgrade cycles across existing and new markets by introducing new technologies. Never hesitating to question the status quo, Aquantia is leading the Multi-Gig revolution.

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

Mantra Bio is harnessing exosomes to deliver safe, highly targeted medicines. We are the creator of REVEAL™, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas.

Chimeras mission is to reprogram life to end cancer, using therapies that restore dignity to patients. We do this with next generation, safer and more potent, CAR T therapeutics.

Our Story: Dr. Rafael Squitieri, Chief of Cardiothoracic Surgery at St. Vincent's Medical Center in Bridgeport, CT, was inspired to transform Critical Care. His inspiration was based on an unforgettable experience with a young patient who underwent successful open-heart surgery but suffered afterward due to complications from a sacral pressure injury. Determined to find a solution for this very common challenge that occurs despite clinicians' best manual efforts and use of the latest therapeutic equipment, Dr. Squitieri set out to devise a system that focuses on preventing blood flow impairment to address the true, underlying problem causing hospital-acquired pressure injuries. In 2011, Dr. Squitieri teamed up with Kim Orumchian, serial entrepreneur and technology expert, to found TurnCare with a vision of creating innovative solutions to protect the most complex critical care patients. Out of their combined vision, they created the Guardian System, which is uniquely designed to prevent sacral region blood flow impairment, providing greater flexibility for clinicians. To date, Dr. Squitieri has helped thousands of patients using this radically different approach; meanwhile improving patient management for bedside clinicians. Contact: TurnCare, Inc. 2225 E. Bayshore Road, Suite 200 Palo Alto, California (203) 505-4657 turncare.com info@turncare.com